Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CardioMiR
- Development stage
- Preclinical
- Lead developer
- Causeway Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CardioMiR is an investigative microRNA-based therapeutic being developed by Causeway Therapeutics for the treatment of heart failure and other cardiovascular diseases. It functions as a microRNA inhibitor (anti-miR) specifically designed to target and neutralize miR-92a. In cardiovascular pathology, miR-92a is known to inhibit angiogenesis and impair endothelial cell function; by suppressing this microRNA, CardioMiR aims to promote blood vessel growth and enhance cardiac repair following injury such as myocardial infarction. The drug represents part of Causeway's pipeline utilizing synthetic oligonucleotides to modulate disease-associated microRNAs.
- Other names
- anti-miR-92aanti-miR92aanti-miR 92amiR-92a inhibitormiR92a inhibitormiR 92a inhibitor
02
Targets
miR-92a (MicroRNA 92a)
Beyond the preview
Go deeper on CardioMiR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CardioMiR.